CAS: 770-71-8; Adamantan-1-Ylmethanol

相似化合物

711-01-3 828-51-3 2094-73-7

上下游产品

CAS号828-51-3 1-金刚烷甲酸 | CAS号711-01-3 1-金刚烷甲酸甲酯 | CAS号201230-82-2 carbon monoxide | CAS号768-93-4 亚硫酸氢钠穿心莲内酯 | CAS号2094-73-7 金刚烷-1-甲酸乙酯 | CAS号2094-74-8 1-金刚烷甲醛 | CAS号778-11-0 金刚烷-1-基甲基 乙酸酯 | CAS号768-90-1 1-溴金刚烷 | CAS号64-18-6 甲酸 | CAS号5511-18-2 1-金刚烷甲酰胺 | CAS号23074-42-2 1-氰基金刚烷 | CAS号5511-18-2 1-金刚烷甲酰胺 | CAS号361441-97-6 N-叔丁氧羰基-L-金刚烷基甘氨酸 | CAS号38584-37-1 3-羟基-1-金刚烷甲醇 | CAS号4942-47-6 1-金刚烷乙酸 | CAS号361442-00-4 N-叔丁氧羰基-3-羟基-1-... | CAS号31685-38-8 3-(1-金刚烷基)-1-丙醇 | CAS号2094-74-8 1-金刚烷甲醛 | CAS号78679-70-6 (1-adamantanyl)... | CAS号828-51-3 1-金刚烷甲酸

1-金刚烷甲酸置于lithium Aluminium Tetrahydride体系中,用 四氢呋喃,乙醚 作为反应溶剂,化学反应 20.0H,以79%的收率获得产物1-金刚烷甲醇
参考文献:有氧氧化伯胺和原位反应生成的胺与格鲁布斯催化剂从醛和铵盐中合成腈
标题:有氧氧化伯胺和原位反应生成的胺与格鲁布斯催化剂从醛和铵盐中合成腈
摘要:本文报道了格鲁布斯催化的伯胺的需氧氧化合成腈的路线.该反应可容纳多种底物,包括简单的伯胺,空间受阻的β,β-二取代胺,烯丙胺,苄胺和α-氨基酯.还指出了与各种官能团的反应相容性,特别是与烯烃,炔烃,卤素,酯,甲硅烷基醚和游离羟基的相容性.腈也是通过醛和nh 4 Oac原位反应生成的亚胺氧化合成的.
DOI:10.1002/adsc.202000663

专利信息

专利号:US-2023212204-A1
优先权日:2020-01-16
标题:Reagents and their use for modular enantiodivergent synthesis of c-p bonds
发明人：XU DONGMIN; RIVAS-BASCÓN NAZARET; KNOUSE KYLE W; PADIAL NATALIA; ZHENG BIN; VANTOUROUT JULIEN; SCHMIDT MICHAEL; EASTGATE MARTIN D; BARAN PHI
权利人:BRISTOL MYERS SQUIBB CO; SCRIPPS RESEARCH INST
摘要:The disclosure describes chiral P(V)-based reagents and their uses for the modular, scalable, and stereospecific synthesis of chiral phosphines, phosphine oxides and particular oligonucleotides.

专利号:US-2008045477-A1
优先权日:2001-06-15
标题 :Series Of New 4,6-Diamino-1,2-Dihydro-1-Aryl-1,3,5-Triazines, Substituted By An Adamantyl Moiety In The Position 2 Of Triazine-Their Corresponding Salts, Isomers,Steroisomers, Enantiomers, Free Bases And The Complexes Of All The Above With Natural Macromolecules And Their Synthetic Derivatives.
发明人：ANTONIADOU-VYZA EKATERINI; TSITSA POLYVXENI; ROUSSAKIS CHRISTOS
权利人:ANTONIADOU-VYZA EKATERINI; TSITSA POLYVXENI; ROUSSAKIS CHRISTOS
摘要:A series of new 4,6-diamino-1,2-dihydro-1-aryl-2-(-tricyclo[3.3.1.1 3,7 ]decyl]-1,3,5-triazines where the aryl group is a substituted or unsubstituted phenyl, or naphthyl-group, as pharmaceutically accepted salts or as free bases. The phenyl group substituents are halides, alkyls, alkoxyls or nitro group. One or more of the above substituents are found one or more times each one, and in various positions of the phenyl group. The corresponding isomers, stereoisomers, enantiomers, free bases and their complexes with various natural macromolecules and synthetic derivatives of them. The invention refers to new and prototype compounds inhibiting the proliferation of unwanted cells that belong to pathogenic microorganisms, to human tissues, to pathological cells, or any pathological cell proliferation. It also refers to the synthesis and the method of synthesis of the above mentioned compounds. The synthesis and the method of synthesis thereof of a series characterized by the preparation of the final triazines, by cyclization of the bigouanide hydrochlorides with adamantane-1-carboxaldehyde. Preparation of the inclusion complexes is realized from compexation of the corresponding hydrochlorides of the above mentioned triazines with natural macromolecules or synthetic derivatives.

专利号:US-2007015793-A1
优先权日:2003-12-23
标 题:Synthesis of nojirimycins
发明人：HIRTH BRADFORD H; RENNIE GLEN
权利人:MACROZYME DNM B V
摘要:Disclosed are methods of preparing substituted nojirimycins represented by the following formula, n n ncomprising reacting 1-deoxynojirimycin with a reagent prepared by reacting an oxidizing agent with the compound represented by the following formula.

专利号:US-2004053999-A1
优先权日:1997-09-17
标题 :Novel compounds and methods for synthesis and therapy
发明人：BISCHOFBERGER NORBERT W; DAHL TERRENCE C; HITCHCOCK MICHAEL J M; KIM CHOUNG U; LEW WILLARD; LIU HONGTAO; MILLS ROGER G; WILLIAMS MATTHEW A
摘要:Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

专利号:US-6225341-B1
优先权日:1995-02-27
标 题:Compounds and methods for synthesis and therapy
发明人：BISCHOFBERGER NORBERT W; KIM CHOUNG U; LEW WILLARD; LIU HONGTAO; WILLIAMS MATTHEW A
权利人:GILEAD SCIENCES INC
摘要:Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

专利号:WO-2014057495-A1
优先权日:2012-10-11
标 题 :A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine
发明人：ALLA VENKAT REDDY; ALLA RAGHU MITRA; DUBEY AJAY KUMAR; REDDY P RAMAKRISHNA
权利人:LEE PHARMA LTD; ALLA VENKAT REDDY; ALLA RAGHU MITRA; DUBEY AJAY KUMAR; REDDY P RAMAKRISHNA
摘要:A commercially viable process for industrial preparation of [(S)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine which is a key intermediate for saxagliptin synthesis and is represented by compound of Formula-VI. The compound-VI obtained by the process of present invention has more than 99.5% HPLC purity, not more than 0.15 % of dihydroxy impurity, not more than 0.05% of isomer impurity and not more than 0.1% of any unknown impurity. Formula (VI).